|
1
|
Martinez-Gonzãlez NA and Sudlow CL:
Effects of apolipoprotein E genotype on outcome after ischaemic
stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J
Neurol Neurosurg Pshychiatry. 77:1329–1335. 2006.
|
|
2
|
Gong X, Fang M, Wang J, et al:
Three-dimensional reconstruction of brain surface anatomy based on
magnetic resonance imaging diffusion-weighted imaging: a new
approach. J Biomed Sci. 11:711–716. 2004.
|
|
3
|
Salvarani C, Brown RD Jr, Calamia KT, et
al: Primary central nervous system vasculitis: analysis of 101
patients. Ann Neurol. 62:442–451. 2007.
|
|
4
|
Wu AH: The ischemia modified albumin
biomarker for myocardial ischemia. MLO Med Lab Obs. 35:36–38.
2003.
|
|
5
|
Sinha MK, Roy D, Gaze DC, Collinson PO and
Kaski JC: Role of ‘ischemia modified albumin’, a new biochemical
marker of myocardial ischemia, in the early diagnosis of acute
coronary syndrome. Emerg Med J. 21:29–34. 2004.
|
|
6
|
Sacchetti A: ‘Ischemia modified albumin’:
a new biochemical marker of myocardial ischemia. Emerg Med J.
21:3–4. 2004.
|
|
7
|
Keating L, Benger JR, Beetham R, et al:
The PRIM A study: presentation of ischemia modified albumin in the
emergency department. Emerg Med J. 23:764–768. 2006.
|
|
8
|
Refaai MA, Wright RW, Parvin CA, et al:
Ischemia-modified albumin increases after skeletal muscle ischemia
during arthroscopic knee surgery. Clin Chim Acta. 366:264–268.
2006.
|
|
9
|
Turedi S, Gunduz A, Mentese, et al: The
value of ischemia-modified albumin in the diagnosis of pulmonary
embolism. AM J Emerg Med. 25:770–773. 2007.
|
|
10
|
Gunduz A, Turedi S, Mentese A, et al:
Ischemia-modified albumin in the diagnosis of acute mesenteric
ischemia: a preliminary study. AM J Emerg Med. 26:202–205.
2009.
|
|
11
|
Gunduz A, Turedi S, Mentese A, et al:
Ischemia-modified albumin levels in cerebrovascular accidents. Am J
Emerg Med. 26:874–878. 2008.
|
|
12
|
Duarte MM, Rocha JB, Moresco RN, et al:
Association between ischemia-modified albumin, lipids and
inflammation biomarkers in patients with hypercholesterolemia. Clin
Biochem. 42:666–671. 2009.
|
|
13
|
Valle Gottlieb MG, da Cruz IB, Duarte MM,
et al: Associations among metabolic syndrome, ischemia,
inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol
Metab. 95:586–591. 2010.
|
|
14
|
Piva SJ, Duarte MM, Da Cruz IB, et al:
Ischemia-modified albumin as an oxidative stress biomarker in
obesity. Clin Biochem. 44:345–347. 2011.
|
|
15
|
Velcheva I, Antonova N, Dimitrova V, et
al: Plasma lipids and blood viscosity in patients with
cerebrovascular disease. Clin Hemorheol Microcirc. 35:155–157.
2006.
|
|
16
|
Kimura Y and Uchiyama S: Hyperlipidemia
and cerebrovascular disease. Nihon Rinsho. 23:685–689. 2001.
|
|
17
|
Moore WS, Barnett HJ, Beebe HG, et al:
Guidelines for carotid endarterectomy. A multidisciplinary
consensus statement from the Ad Hoc Committee, American Heart
Association. Circulation. 91:566–579. 1995.
|
|
18
|
Pappachan J and Kirkham FJ:
Cerebrovascular disease and stroke. Arch Dis Child. 93:890–898.
2008.
|
|
19
|
Roy D, Quiles J, Sharma R, et al:
Ischemia-modified albumin concentrations in patients with
peripheral vascular disease and exercise-induced skeletal muscle
ischemia. Clin Chem. 50:1656–1680. 2004.
|
|
20
|
Lippi G, Montagnana M and Guidi GC:
Albumin cobalt binding and ischemia modified albumin generation: an
endogenous response to ischemia. Int J Cardiol. 108:410–411.
2006.
|
|
21
|
Abboud H, Labreuche J, Meseguer E, et al:
Ischemia-modified albumin in acute stroke. Cerebrovasc Dis.
23:216–220. 2007.
|
|
22
|
Wei LX, Tang QH, Sun L, et al:
Relationship between oxidized lipoprotein, angiogenesis and human
coronary atherosclerotic plaque stabilization. Zhonghua Bing Li Xue
Za Zhi. 35:138–141. 2006.
|
|
23
|
Bhagavan NV, Ha JS, Park JH, et al:
Utility of serum fatty acid concentrations as a marker for acute
myocardial infarction and their potential role in the formation of
ischemia-modified albumin: a pilot study. Clin Chem. 55:1588–1590.
2009.
|
